Xiao Chaihutang， originating from the Treatise on Typhoid and Miscellaneous Diseases， is a classic formula for harmonizing the Shaoyang. It excels in regulating the pivotal mechanism and unblocking the triple energizer， corresponding to the pathogenesis of digestive system tumors characterized by the interlocking of deficiency， stasis， phlegm， and toxicity， as well as disharmony between Yin and Yang. This paper systematically reviews research findings from China and abroad over the past decade， exploring the anti-tumor effects of Xiao Chaihutang on digestive system tumors from three dimensions： theoretical rationale， clinical efficacy， and molecular mechanisms. At the level of principle and method， Xiao Chaihutang takes "harmonization" as its core therapeutic guideline. By reconciling the exterior and interior to restore the Shaoyang pivot， harmonizing Yin and Yang to improve the tumor microenvironment， and regulating the liver and spleen to consolidate and protect the foundation of postnatal essence， it promotes the restoration of the body's dynamic balance of Yin and Yang. Clinical studies have demonstrated that Xiao Chaihutang， used alone or in combination with modern medical therapies， shows definite efficacy against digestive system tumors such as hepatocellular carcinoma， pancreatic carcinoma， and gastrointestinal carcinoma. It can significantly improve patients' quality of life， inhibit tumor progression， effectively relieve concomitant symptoms such a s cancer-related fever， anxiety， depression， and insomnia， and alleviate postoperative embolic syndromes as well as adverse reactions to radiotherapy and chemotherapy. Experimental studies have revealed that Xiao Chaihutang can inhibit tumor cell proliferation， induce apoptosis， arrest the cell cycle， suppress tumor cell invasion and metastasis， and improve the tumor microenvironment. Through the above analysis， this study elucidates the current clinical and experimental research status of Xiao Chaihutang in the treatment of digestive system tumors， aiming to provide theoretical support for its precise clinical application. On this basis， it further explores key issues in the identification of pharmacodynamic substances and the accumulation of evidence in evidence-based medicine， thereby offering a new perspective for the innovative development of integrative Chinese and Western medicine in synergistic cancer therapy.

Objective:To analyze the changes in the incidence trend of liver cancer in Taizhou of Jiangsu Province, from 2012 to 2020 and provide reference for tumor prevention and control and management.Methods:Liver cancer incidence data from 2012 to 2020 were extracted from the Taizhou Center for Disease Control and Prevention's tumor registry system. Demographic data were used to calculate the crude incidence rate, age-standardized incidence rate (ASIR), Chinese age-standardized incidence rate (CASIR; based on China's 2010 standard population), and world age-standardized incidence rate (WASIR; based on Segi's world standard population). The Joinpoint regression model was applied to identify inflection points in liver cancer incidence trends during 2012-2020, and annual percentage change (APC) with average annual percentage change (AAPC) were calculated.Results:In 2020, the crude incidence ratio (CIR) of liver cancer in Taizhou was 34.6 per 100 000, with CASIR and WASIR at 19.6 per 100 000 and 14.9 per 100 000, respectively. From 2012 to 2020, the male-to-female ratio of new liver cancer cases was 2.94∶1 (10 455 males vs. 3 559 females), with male incidence consistently higher than female. Overall liver cancer incidence in Taizhou initially increased and then decreased after 2017 (2012-2017: APC=6.4%, P=0.014; 2017-2020: APC=-9.5%, P=0.035), peaking at a CASIR of 26.2 per 100 000 in 2017. The trend in male incidence mirrored the overall pattern, rising before 2017 and declining thereafter (2012-2017: APC=6.2%, P=0.005; 2017-2020: APC=-9.0%, P=0.016). Female incidence remained relatively stable (2012-2016: APC=11.0%, P=0.054; 2016-2020: APC=-6.5%, P=0.130). Conclusions:Liver cancer incidence in Taizhou increased before 2017 and declined thereafter, with 2017 as the turning point. Amid population aging, liver cancer remains a persistent public health challenge requiring sustained attention.

Objective:To investigate the effects of PRND downregulation on the proliferation, migration, and invasion capabilities of human renal carcinoma cells.Methods:Clinical and transcriptomic data from renal carcinoma patients were analyzed using the TCGA database, with bioinformatics methods employed for differential gene expression analysis and survival analysis [including overall survival (OS) and disease-free survival (DFS)]. Postoperative pathological specimens from 50 renal carcinoma patients admitted to Affiliated Cancer Hospital of Zhengzhou University between January 2022 and January 2023 were collected for immunohistochemical staining to assess PRND expression in renal carcinoma tissues. Two distinct small interfering RNAs (siRNAs) were used to downregulate PRND expression in renal carcinoma cell lines ACHN and 769P. Quantitative real-time polymerase chain reaction (qPCR) and Western blotting were performed to validate the knockdown efficiency of PRND at the mRNA and protein levels. The proliferation, migration, and invasion capabilities of ACHN and 769P cells were evaluated using the Cell Counting Kit-8 (CCK-8), cell migration assay, and invasion assay, which was compared between the negative control group (NC) and the two PRND knockdown groups (si1 and si2). Western blotting was used to measure the expression levels of MMP-9, E-cadherin, C-myc, Vimentin, β-catenin, and PD-L1 proteins in ACHN and 769P cell lines.Results:TCGA database analysis revealed that PRND expression was significantly higher in renal carcinoma tissues compared with adjacent normal tissues (1.172 vs. 0.383, P<0.01). Survival analysis indicated that high PRND expression was significantly negatively correlated with both OS ( P<0.01) and DFS ( P<0.01). CCK-8 assay results showed no statistically significant differences in cell viability between the experimental and control groups at 6 hours (ACHN-si1: 1.238±0.659, ACHN-si2: 1.437±0.359, ACHN-NC: 3.234±2.165, P>0.05). However, significant differences were observed at 24 hours (ACHN-si1: 5.608±0.716, ACHN-si2: 7.088±0.308, ACHN-NC: 9.764±1.088, P<0.01), 48 hours (ACHN-si1: 40.422±1.419, ACHN-si2: 41.238±2.623, ACHN-NC: 65.823±4.337, P<0.01), and 72 hours (ACHN-si1: 53.667±4.565, ACHN-si2: 54.533±2.572, ACHN-NC: 78.800±0.265, P<0.01). Similar trends were observed in 769P cells (6 hours: P>0.05; 24 hours: P<0.05; 48 and 72 hours: P<0.01). Cell migration assays demonstrated significantly reduced migration in the experimental groups (ACHN-si1: 31±10, ACHN-si2: 62±19, ACHN-NC: 175±45, P<0.01; 769P-si1: 79±16, 769P-si2: 62±14, 769P-NC: 236±77, P<0.05). Invasion assays also showed significant suppression in the experimental groups (ACHN-si1: 13±9, ACHN-si2: 15±8, ACHN-NC: 54±12, P<0.01; 769P-si1: 17±13, 769P-si2: 19±17, 769P-NC: 91±29, P<0.01). Western blotting revealed that C-myc, β-catenin, MMP-9, Vimentin, and PD-L1 protein levels were lower in the experimental groups, while E-cadherin expression was higher compared to the control groups. Conclusions:PRND is significantly overexpressed in renal carcinoma tissues and closely associated with poor patient prognosis. Downregulation of PRND markedly inhibits the proliferation, migration, and invasion of renal carcinoma cells, potentially through modulation of epithelial-mesenchymal transition (EMT)-related proteins and key molecules involved in tumor metastasis.

Obesity, as a chronic recurrent disease, has become a major public health challenge in China. To implement the requirements of the Healthy China Initiative (2019—2030), under domestic guidelines or consensus statements on overweight and obesity, and in alignment with the latest scientific advances globally, the Quality control protocol for adult overweight and obesity screening in health management (examination) institutions (2025 edition) was developed. This protocol was drafted by the Health Management Center of Shanghai Changzheng Hospital and formulated through multiple rounds of deliberation by experts in China’s health examination quality control field. The protocol establishes unified standards for screening facilities, personnel qualifications, and measurement or testing procedures. It defines specific screening items, outlines a standardized screening pathway, and sets requirements for the final medical review, ensuring the scientific validity, effectiveness, and safety of the screening process. The implementation of this protocol will enhance the consistency of weight management practices for adults across health examination institutions and strengthen the quality control of overweight and obesity screening programs.

Objective:To analyze the changes in the incidence trend of liver cancer in Taizhou of Jiangsu Province, from 2012 to 2020 and provide reference for tumor prevention and control and management.Methods:Liver cancer incidence data from 2012 to 2020 were extracted from the Taizhou Center for Disease Control and Prevention's tumor registry system. Demographic data were used to calculate the crude incidence rate, age-standardized incidence rate (ASIR), Chinese age-standardized incidence rate (CASIR; based on China's 2010 standard population), and world age-standardized incidence rate (WASIR; based on Segi's world standard population). The Joinpoint regression model was applied to identify inflection points in liver cancer incidence trends during 2012-2020, and annual percentage change (APC) with average annual percentage change (AAPC) were calculated.Results:In 2020, the crude incidence ratio (CIR) of liver cancer in Taizhou was 34.6 per 100 000, with CASIR and WASIR at 19.6 per 100 000 and 14.9 per 100 000, respectively. From 2012 to 2020, the male-to-female ratio of new liver cancer cases was 2.94∶1 (10 455 males vs. 3 559 females), with male incidence consistently higher than female. Overall liver cancer incidence in Taizhou initially increased and then decreased after 2017 (2012-2017: APC=6.4%, P=0.014; 2017-2020: APC=-9.5%, P=0.035), peaking at a CASIR of 26.2 per 100 000 in 2017. The trend in male incidence mirrored the overall pattern, rising before 2017 and declining thereafter (2012-2017: APC=6.2%, P=0.005; 2017-2020: APC=-9.0%, P=0.016). Female incidence remained relatively stable (2012-2016: APC=11.0%, P=0.054; 2016-2020: APC=-6.5%, P=0.130). Conclusions:Liver cancer incidence in Taizhou increased before 2017 and declined thereafter, with 2017 as the turning point. Amid population aging, liver cancer remains a persistent public health challenge requiring sustained attention.

Objective:To investigate the effects of PRND downregulation on the proliferation, migration, and invasion capabilities of human renal carcinoma cells.Methods:Clinical and transcriptomic data from renal carcinoma patients were analyzed using the TCGA database, with bioinformatics methods employed for differential gene expression analysis and survival analysis [including overall survival (OS) and disease-free survival (DFS)]. Postoperative pathological specimens from 50 renal carcinoma patients admitted to Affiliated Cancer Hospital of Zhengzhou University between January 2022 and January 2023 were collected for immunohistochemical staining to assess PRND expression in renal carcinoma tissues. Two distinct small interfering RNAs (siRNAs) were used to downregulate PRND expression in renal carcinoma cell lines ACHN and 769P. Quantitative real-time polymerase chain reaction (qPCR) and Western blotting were performed to validate the knockdown efficiency of PRND at the mRNA and protein levels. The proliferation, migration, and invasion capabilities of ACHN and 769P cells were evaluated using the Cell Counting Kit-8 (CCK-8), cell migration assay, and invasion assay, which was compared between the negative control group (NC) and the two PRND knockdown groups (si1 and si2). Western blotting was used to measure the expression levels of MMP-9, E-cadherin, C-myc, Vimentin, β-catenin, and PD-L1 proteins in ACHN and 769P cell lines.Results:TCGA database analysis revealed that PRND expression was significantly higher in renal carcinoma tissues compared with adjacent normal tissues (1.172 vs. 0.383, P<0.01). Survival analysis indicated that high PRND expression was significantly negatively correlated with both OS ( P<0.01) and DFS ( P<0.01). CCK-8 assay results showed no statistically significant differences in cell viability between the experimental and control groups at 6 hours (ACHN-si1: 1.238±0.659, ACHN-si2: 1.437±0.359, ACHN-NC: 3.234±2.165, P>0.05). However, significant differences were observed at 24 hours (ACHN-si1: 5.608±0.716, ACHN-si2: 7.088±0.308, ACHN-NC: 9.764±1.088, P<0.01), 48 hours (ACHN-si1: 40.422±1.419, ACHN-si2: 41.238±2.623, ACHN-NC: 65.823±4.337, P<0.01), and 72 hours (ACHN-si1: 53.667±4.565, ACHN-si2: 54.533±2.572, ACHN-NC: 78.800±0.265, P<0.01). Similar trends were observed in 769P cells (6 hours: P>0.05; 24 hours: P<0.05; 48 and 72 hours: P<0.01). Cell migration assays demonstrated significantly reduced migration in the experimental groups (ACHN-si1: 31±10, ACHN-si2: 62±19, ACHN-NC: 175±45, P<0.01; 769P-si1: 79±16, 769P-si2: 62±14, 769P-NC: 236±77, P<0.05). Invasion assays also showed significant suppression in the experimental groups (ACHN-si1: 13±9, ACHN-si2: 15±8, ACHN-NC: 54±12, P<0.01; 769P-si1: 17±13, 769P-si2: 19±17, 769P-NC: 91±29, P<0.01). Western blotting revealed that C-myc, β-catenin, MMP-9, Vimentin, and PD-L1 protein levels were lower in the experimental groups, while E-cadherin expression was higher compared to the control groups. Conclusions:PRND is significantly overexpressed in renal carcinoma tissues and closely associated with poor patient prognosis. Downregulation of PRND markedly inhibits the proliferation, migration, and invasion of renal carcinoma cells, potentially through modulation of epithelial-mesenchymal transition (EMT)-related proteins and key molecules involved in tumor metastasis.

Background and purpose:Human epidermal growth factor receptor 2(HER2)is closely associated with drug efficacy and prognosis in urothelial carcinoma(UC).HER2 is a significant biomarker and therapeutic target in various tumors.In recent years,anti-HER2 antibody-drug conjugates have shown significant clinical efficacy in UC patients with HER2 overexpression.Therefore,an in-depth understanding of HER2 expression and its characteristics in Chinese UC patients is crucial to guide treatment decision-making,optimize treatment strategies and achieve personalized therapy.This study aimed to thoroughly investigate correlation of HER2 expression and clinicopathological characteristics in Chinese patients with UC.Methods:This study was a multicenter study that retrospectively included UC patients from urology departments of 8 tertiary hospitals in 5 geographical regions of China(North China,East China,South China,Central China and Northwest)whose tissue samples were collected from January 2023 to March 2024.Inclusion criteria:① age above 18 years;② UC diagnosed by histopathological or cytological examination;③ complete results of HER2 expression detection using immunohistochemistry(IHC)in the primary tumor site were required.Exclusion criteria:① diagnosed patients with tumors in other parts of the body;② physicians evaluated other situations that were not suitable for inclusion in this study.IHC results for HER2 expression and clinicopathological data were collected.HER2 expression was determined according to the criteria outlined in"Clinical pathological expert consensus on HER2 testing in urothelial carcinoma in China",with HER2 2+and 3+defined as HER2 overexpression.The HER2 expression and clinicopathological features were analyzed.This study was approved by the medical ethics committee of Fudan University Shanghai Cancer Center(ethical number:2301268-12)and was registered at China Clinical Trial Registry(registration number:ChiCTR2300069746).Results:A total of 1054 patients with UC were included.Most of the tumors were bladder UC(n=807,76.6%).The mean age of patients was(66.8±10.5)years,and the majority were male(78.5%).The HER2 overexpression rate was 58.4%(n=616),with an additional 23%of patients having HER2 1+expression(n=242),and a small proportion exhibiting negative HER2 expression(n=196,18.6%).HER2 expression was significantly associated with various clinical and pathological characteristics such as Eastern Cooperative Oncology Group(ECOG)performance status,history of cardiovascular disease,history of metabolic disorders,smoking,UC disease location,differentiation grade,pathological type,and tumor stage.Conclusion:Retrospective analysis of multi-center data shows that HER2 expression is frequently observed in Chinese UC patients,with an overexpression rate of up to 58.4%.Furthermore,HER2 expression is closely associated with various clinical and pathological features of UC patients.This study underscores the critical importance of accurately assessing HER2 expression in UC patient to guide personalized therapies.

Objective To investigate the expression of trophoblast cell-surface antigen 2(TROP2)in salivary ade-noid cystic carcinoma(SACC)in order to analyze its relationship with TROP2 expression and clinicopathological features,as well as to clarify the correlation between TROP2 expression and the prognosis of patients with SACC.Methods With approval from the ethics committee,the expression of TROP2 in 85 SACC and paracancer tissue sam-ples was detected by using the immunohistochemical method,and the relationship between TROP2 expression and clini-copathological characteristics was analyzed.The Kaplan-Meier method was used to analyze the relationship between TROP2 protein expression and 5-year disease-free survival(DFS)in 40 patients with SACC.Furthermore,the logistic re-gression model was used to analyze the prognostic factors of patients with SACC.Results The low or no expression rate of TROP2 in SACC tissues was significantly higher than that in paracancer tissues(P＜0.001).Low or no expres-sion of TROP2 was significantly positively correlated with tumor growth and clinical staging in patients with SACC(P＜0.05).Kaplan-Meier survival analysis showed that the DFS of patients with SACC with low or no expression of TROP2 protein was significantly lower than those of patients with high expression of TROP2 protein(P＜0.05),and the progno-sis was poor.The logistic regression model showed that low or no expression of TROP2 protein(OR=5.37;95%CI:1.03-28.08;P=0.046)and Ⅲ-Ⅳ clinical staging(OR=6.89;95%CI:1.37～34.77;P=0.019)were risk factors affect-ing the prognosis of patients with SACC.Conclusion Low or no expression of TROP2 protein in SACC tissues leads to poor prognosis of patients and is positively correlated with tumor growth and clinical staging.In addition,low or no ex-pression of TROP2 can be used as an independent prognostic risk factor for poor prognosis in patients with SACC,and TROP2 is a marker of poor prognosis in patients with SACC.

[This corrects the article DOI: 10.1016/j.chmed.2022.08.005.].

Objective To improve the quality of prescriptions and promote the rational drug application of Dingqing Tablets by investigating the outpatient prescriptions in a tertiary A hospital. Methods A total of 4 796 prescriptions of outpatient pharmacy patients from August 1, 2020 to August 1, 2021 were extracted from the hospital information system by the hospital information software, focusing on the analysis of indications, usage and dosage, drug interaction, etc. Results 10 departments including hematology department and geriatrics department were used Dingqing Tablets, and the irrationality was mainly manifested in the superposition of drug flavors and drug interactions. Conclusion Dingqing tablets were widely used in clinic and had remarkable curative effect. However, there are certain risks in the use of Dingqing tablets. It is necessary to add medication education and supervision to promote the safe and rational use of drugs in clinic.